Novartis to Buy Myricx Bio for Up to $1.5 Billion
Novartis is expanding its antibody-drug conjugate (ADC) pipeline through the acquisition of U.K.-based cancer biotech Myricx Bio for up to $1.5 billion.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
📍 How it ended
Novartis agreed to acquire U.K. cancer biotech firm Myricx Bio for up to $1.5 billion. The deal included an upfront payment of $1.1 billion to expand Novartis' ADC pipeline.
Epilogue added 18d ago, after coverage quieted.
The brief
Novartis has reached an agreement to acquire Myricx Bio, a cancer biotech firm based in the United Kingdom. The deal is valued at up to $1.5 billion, with Fierce Biotech reporting an upfront payment of $1.1 billion.
Coverage from Bloomberg, The Wall Street Journal, and the Financial Times emphasizes the total valuation of the deal. Reports from qz.com and Business Wire confirm the acquisition of the U.K. entity, while Fierce Biotech notes the strategic move to expand Novartis's ADC pipeline.
Future developments depend on the completion of the acquisition and the integration of Myricx Bio's technology into the Novartis pipeline.
Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 19d ago.
Quick answers
What is the total value of the Novartis-Myricx Bio deal?
The deal is valued at up to $1.5 billion.
How much is Novartis paying upfront?
According to Fierce Biotech, Novartis will pay $1.1 billion upfront.
Where is Myricx Bio located?
Myricx Bio is a biotech firm based in the United Kingdom.
Coverage (7)
- Four major biotech updates to catch up on STAT · 21d ago
- Novartis acquires U.K. cancer biotech Myricx Bio for $1.5 billion qz.com · 21d ago
- Sofinnova Partners Announces Myricx Bio Agrees to Be Acquired by Novartis Business Wire · 21d ago
- Novartis to buy UK biotech Myricx Bio in $1.5bn deal Financial Times · 21d ago
- Novartis to pay $1.1B upfront for Myricx to expand ADC pipeline Fierce Biotech · 21d ago
- Novartis to Buy Cancer-Drug Firm Myricx for Up to $1.5 Billion Bloomberg.com · 21d ago
- Novartis to Buy Myricx Bio for Up to $1.5 Billion WSJ · 21d ago
Topics
Related trends
Argenx to Buy Forte Biosciences for $2.2 Billion
Argenx is expanding its immunology pipeline with a $2.2 billion acquisition of autoimmune biotech firm Forte Biosciences.
The 'Surprisingly Soft' Unit That Caused Danaher To Plummet
Danaher shares are sliding despite a second-quarter earnings beat and raised guidance, driven by a "surprisingly soft" business unit.
Creatine supplements may help halt cancer growth, study suggests
New research is sparking conflicting reports on whether creatine supplements inhibit cancer growth or potentially boost tumor metastasis.
Kids with deadliest brain cancers survive years after breakthrough cell therapy
6 news sources are covering this Health story right now — Archynetys is tracking how fast it spreads.
Scientists Finally Learned How a Tiny Mouse Survives Near the Andes Death Zone at 7,000 Meters
7 news sources are covering this Science story right now — Archynetys is tracking how fast it spreads.
Kalshi Will Offer Sports-Style Betting on Drug Trial Results
Prediction platform Kalshi is launching sports-style betting markets focused on biotech clinical trials and FDA drug approvals.